1229236-85-4

Basic information

• Product Name: 6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine
• Synonyms: 6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine;4-((6-chloro-3-(4-chloro-2-fluorobenzyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine
• CAS NO: 1229236-85-4
• Molecular Formula: C₁₉H₁₉Cl₂FN₄O
• Molecular Weight: 409.2847632
• Mol File: 1229236-85-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine(1229236-85-4)
• EPA Substance Registry System: 6-chloro-3-(4-chloro-2-fluorobenzyl)-2-Methyl-8-(Morpholin-4-ylMethyl)iMidazo[1,2-b]pyridazine(1229236-85-4)

Safety Data

• Hazardous Substances Data: 1229236-85-4(Hazardous Substances Data)

Usage

Molecular structure

Consists of a pyridazine core with various substituted aryl and alkyl groups

Medicinal chemistry use

Potential drug candidate for the treatment of certain diseases and disorders

Heterocyclic structure

Contains heteroatoms in the ring structure, contributing to its pharmacological properties

Biological interactions

Specific interactions with biological targets and modulation of cellular processes

Ongoing research

Its role in pharmacology and therapeutic potential is currently under investigation

Clinical applicability

Further studies needed to understand its usefulness in clinical settings.

Upstream product

• 1229236-84-3 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-3-yl)methanol 
• 1229236-83-2 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-3-yl)methanone 
• 1422006-68-5 4-((6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)morpholine 
• 87417-71-8 4-chloro-1-(chloromethyl)-2-fluorobenzene 
• 14714-18-2 ethyl 6-Chloro-2-methylimidazo[1,2-b]pyridazine-3-carboxylate 
• 299411-67-9 2-chloro-1-(4-chloro-2-fluorophenyl)ethan-1-one 
• 175711-83-8 4’-chloro-2’-fluoroacetophenone 
• 1229236-80-9 (4-chloro-2-fluorophenyl)(6-chloro-2-methylimidazo-[1,2-b]pyridazin-3-yl)methanone 
• 1229236-79-6 (E)-N'-(6-chloropyridazin-3-yl)-N,N-dimethylacetimidamide 

Downstream Products

• 1229236-86-5 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-6-amine 
• 1346221-91-7 N-(1-tert-butyl-3-methyl-1H-pyrazol-5-yl)-3-(4-chloro-2-fluorobenzyl)-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine 

Relevant articles and documents

Development of an alternate synthesis for a key JAK2 inhibitor intermediate via sequential c-h bond functionalization

The development of an alternative synthetic route to a functionalized imidazopyridazine which strategically streamlines the synthesis and avoids a number of problematic reagents is described. Key to the success of this alternative route is the use of two

Development of a Stepwise Reductive Deoxygenation Process by Ru-Catalysed Homogeneous Ketone Reduction and Pd-Catalysed Hydrogenolysis in the Presence of Cu Salts

A stepwise catalytic reduction of ketone 1 to alcohol 2 and subsequently to aryl(imidazo[1,2-b]pyridazinyl)methane 3 is described, which provides synthetically useful chemoselectivity at acceptably low catalyst loadings. Undesired reactive sites include a

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.